EUVIMEDEUVIMED entdecken
Multizentrische StudieKlinische Studie (Phase II)Open Access

Atezolizumab and Stereotactic Body Radiation in Metastatic, Recurrent, or Persistent Cervical Cancer: Results From a Phase 2 Multi-Institutional Study

Kamran A Ahmed, Allison M Quick, Hye Sook Chon, Jing-Yi Chern, Kristin Bixel, Youngchul Kim, Jiannong Li, Michael E Montejo, Robin A Dowell, Sungjune Kim, Daniel C Fernandez, Cesar A Lam und 5 weitere

International Journal of Radiation Oncology*Biology*Physics · 2026

DOI: 10.1016/j.ijrobp.2025.05.003 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift International Journal of Radiation Oncology*Biology*Physics, 2026. Verfasst von Kamran A Ahmed und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, Moffitt Cancer Center, Tampa, Florida. Electronic address: kamran.ahmed@moffitt.org. Hauptthemen laut MEDLINE: Uterine Cervical Neoplasms, Antibodies, Monoclonal, Humanized, Radiosurgery, Neoplasm Recurrence, Local. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, Genentech Inc, Moffitt Cancer Center.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Pembrolizumab is approved for PD-L1+ but not PD-L1 negative metastatic, recurrent, or persistent cervical cancer. Response rates to single agent anti-PD-1/PD-L1 therapy have been modest with no responses noted in PD-L1 negative tumors. METHODS AND MATERIALS: The study is designed as a prospective, phase II multi-institutional trial of stereotactic body radiation therapy (SBRT) followed by atezolizumab (1200 mg intravenously q3 weeks). Key eligibility criteria included patients with metastatic, recurrent, or persistent cervical cancer with at least 2 distinct lesions. The primary objective was objective response rate measured at the unirradiated target lesion. RESULTS: A total of 21 patients were enrolled. Median follow-up is 23.6 months. The majority of patients had adenocarcinoma (n = 10; 48%) and were PD-L1 negative (n = 15; 71%). The best overall response was a partial response in 5 (24%) and stable disease in 12 (57%) patients. The median duration of response was 8.6 months (95% CI, 4.5-13.6 months). An objective response at the unirradiated target lesion was observed in 8 patients (38%), meeting the study defined endpoint. Responses were noted in PD-L1 negative tumors. The most common grade ≥2 toxicities at least possibly attributed to study therapy included lymphopenia (n = 6; 29%), nausea/vomiting (n = 3; 14%), and hyponatremia (n = 3; 14%). CONCLUSIONS: In this first trial of SBRT and atezolizumab in metastatic cervical cancer unselected for PD-L1, combination therapy was well tolerated. Responses were noted in PD-L1 negative tumors. Combination therapy may allow for improved response rates to immune checkpoint inhibition in metastatic cervical cancer particularly in PD-L1 negative tumors.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Uterine Cervical NeoplasmsAntibodies, Monoclonal, HumanizedRadiosurgeryNeoplasm Recurrence, LocalHumansFemaleMiddle AgedAgedAdultProspective StudiesCombined Modality TherapyAged, 80 and overB7-H1 AntigenNeoplasm MetastasisImmune Checkpoint Inhibitors

Substanzen

Antibodies, Monoclonal, HumanizedatezolizumabB7-H1 AntigenImmune Checkpoint Inhibitors

Autor:innen und Institutionen

  • Department of Radiation Oncology, Moffitt Cancer Center, Tampa, Florida. Electronic address: kamran.ahmed@moffitt.org.
  • Department of Radiation Oncology, Ohio State, University, Ohio State University, Columbus, Ohio.
  • Department of Gynecologic Oncology, Moffitt Cancer Center, Tampa, Florida.
  • Department of Gynecologic Oncology, Stanford University, Palo Alto, California.
  • Department of Biostatistics, Moffitt Cancer Center, Tampa, Florida.
  • Department of Radiation Oncology, Moffitt Cancer Center, Tampa, Florida.

Förderung

  • NCI NIH HHS
  • Genentech Inc
  • Moffitt Cancer Center

Zitieren

APA

Ahmed, K. A., Quick, A. M., Chon, H. S., Chern, J. Y., Bixel, K., Kim, Y., Li, J., Montejo, M. E., Dowell, R. A., Kim, S., Fernandez, D. C., Lam, C. A., Hakam, A., Rosa, M., Shafique, M., Shahzad, M. M., & Wenham, R. M. (2026). Atezolizumab and Stereotactic Body Radiation in Metastatic, Recurrent, or Persistent Cervical Cancer: Results From a Phase 2 Multi-Institutional Study. International Journal of Radiation Oncology*Biology*Physics. https://doi.org/10.1016/j.ijrobp.2025.05.003

Vancouver

Ahmed KA, Quick AM, Chon HS, Chern JY, Bixel K, Kim Y, et al. Atezolizumab and Stereotactic Body Radiation in Metastatic, Recurrent, or Persistent Cervical Cancer: Results From a Phase 2 Multi-Institutional Study. International Journal of Radiation Oncology*Biology*Physics. 2026. doi:10.1016/j.ijrobp.2025.05.003

BibTeX
@article{Ahmed2026,
  author = {Ahmed, Kamran A and Quick, Allison M and Chon, Hye Sook and Chern, Jing-Yi and Bixel, Kristin and Kim, Youngchul and Li, Jiannong and Montejo, Michael E and Dowell, Robin A and Kim, Sungjune and Fernandez, Daniel C and Lam, Cesar A and Hakam, Ardeshir and Rosa, Marilin and Shafique, Michael and Shahzad, Mian M and Wenham, Robert M},
  title = {Atezolizumab and Stereotactic Body Radiation in Metastatic, Recurrent, or Persistent Cervical Cancer: Results From a Phase 2 Multi-Institutional Study},
  journal = {International Journal of Radiation Oncology*Biology*Physics},
  year = {2026},
  doi = {10.1016/j.ijrobp.2025.05.003}
}
Kostenlos starten →